ROBERT BROWN: Open Payments
NPI 1487610879 · MINDEN, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,443 in 76 payments from 16 companies in 2025. Trend: 2023 $767 · 2024 $640 · 2025 $1,443
Food & beverage: $1,355Education: $89
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $248 |
| Alkermes, Inc. | 13 | $166 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $155 |
| Axsome Therapeutics, Inc. | 9 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $130 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| Vanda Pharmaceuticals Inc. | 2 | $100 |
| Astellas Pharma US Inc | 1 | $85 |
| Novo Nordisk Inc | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
Products named: VRAYLAR, ARISTADA, Kerendia, Auvelity, REXULTI, CAPLYTA, FANAPT, TRINTELLIX.
Industry payments across LA — which companies pay providers there.
